0
selected
-
1.
Adipokines underlie the early origins of obesity and associated metabolic comorbidities in the offspring of women with pregestational obesity.
Arroyo-Jousse, V, Jaramillo, A, Castaño-Moreno, E, Lépez, M, Carrasco-Negüe, K, Casanello, P
Biochimica et biophysica acta. Molecular basis of disease. 2020;(2):165558
Abstract
Maternal pregestational obesity is a well-known risk factor for offspring obesity, metabolic syndrome, cardiovascular disease and type 2 diabetes. The mechanisms by which maternal obesity can induce alterations in fetal and later neonatal metabolism are not fully elucidated due to its complexity and multifactorial causes. Two adipokines, leptin and adiponectin, are involved in fetal and postnatal growth trajectories, and both are altered in women with pregestational obesity. The placenta synthesizes leptin, which goes mainly to the maternal circulation and in lesser amount to the developing fetus. Maternal pregestational obesity and hyperleptinemia are associated with placental dysfunction and changes in nutrient transporters which directly affect fetal growth and development. By the other side, the embryo can produce its own leptin from early in development, which is associated to fetal weight and adiposity. Adiponectin, an insulin-sensitizing adipokine, is downregulated in maternal obesity. High molecular weight (HMW) adiponectin is the most abundant form and with most biological actions. In maternal obesity lower total and HMW adiponectin levels have been described in the mother, paralleled with high levels in the umbilical cord. Several studies have found that cord blood adiponectin levels are related with postnatal growth trajectories, and it has been suggested that low adiponectin levels in women with pregestational obesity enhance placental insulin sensitivity and activation of placental amino acid transport systems, supporting fetal overgrowth. The possible mechanisms by which maternal pregestational obesity, focusing in the actions of leptin and adiponectin, affects the fetal development and postnatal growth trajectories in their offspring are discussed.
-
2.
Adipokines as novel biomarkers of cardio-metabolic disorders.
Su, X, Peng, D
Clinica chimica acta; international journal of clinical chemistry. 2020;:31-38
Abstract
Obesity, defined as having a body mass index (BMI) greater than 30 kg/m2, has been verified to be associated with several health problems which are always grouped as metabolic syndrome. However, the underlying pathogenic mechanisms remain unclear. The hallmarks of obesity are dysfunctional changes in adipose tissue and dyslipidemia characterized by elevated serum levels of low density lipoprotein cholesterol (LDL-C), very low density lipoprotein cholesterol (VLDL-C), and reduced serum levels of high density lipoprotein cholesterol (HDL-C). Currently, it is widely accepted that rather than being a reservoir for energy storage, the adipose tissue could also secrete multiple hormones and molecules, named adipokines. Notably, growing evidence has put forward that under obese status, the adipocytes are dysfunctional with excessive secretion of multiple pro-inflammatory adipokines, contributing to a chronic inflammatory reaction and promote the progression of metabolic and cardiovascular complications. Although some adipokines have been shown to be causally linked to various disease processes, the functions of other novel adipokines in modulating diseases are still not elucidated. In this review, we focus on the microenvironment of adipose tissue and how it influences obesity and cardiovascular disorders. We also summarize the role of adipokines in modulating systemic inflammatory responses that contribute to cardio-metabolic disorders.
-
3.
The Adipokine-Cardiovascular-Lifestyle Network: Translation to Clinical Practice.
Mechanick, JI, Zhao, S, Garvey, WT
Journal of the American College of Cardiology. 2016;(16):1785-1803
Abstract
Adipokines are peptides, secreted by adipocytes and other cell types with targets in other tissues, participating in a complex network of humoral factors involved in obesity, insulin resistance, and cardiovascular (CV) disease. This review describes recent information about adipokine effects on the CV system. Rather than simply providing a listing of adipokines and their respective effects, network analysis is used to enhance understanding. Various relationships and emergent processes in the adipokine-CV system network are discussed, with the most significant interactors being responses to hypoxia, regulation of cell migration, effects on blood coagulation, and platelet activation. Clinical translation is provided through network representations of the "obesity paradox," "metabolically healthy obese," "metabolic syndrome," and beneficial role of lifestyle medicine. As more translatable information about the larger adipokine-CV-lifestyle network is acquired from laboratory and clinical research, the strategic and precise role of lifestyle intervention can be fashioned to improve CV outcomes.
-
4.
Novel adipokines: their potential role in the pathogenesis of obesity and metabolic disorders.
Korek, E, Krauss, H
Postepy higieny i medycyny doswiadczalnej (Online). 2015;(0):799-810
Abstract
Since identification in 1994 of leptin, a hormone produced by adipocytes, adipose tissue has become the subject of intensive research. These studies contributed to the discovery that adipocytes have the ability to synthesize and secrete biologically active substances called "adipokines". Adipokines include a variety of cytokines, peptide hormones and enzymes that play a role in a wide variety of biological functions. For example, they are involved in the regulation of appetite, energy homeostasis, vascular hemostasis, blood pressure, inflammatory and immune processes and play a role in the metabolism of carbohydrates and fats. In obese patients, the secretion of adipokines is frequently abnormal. These changes may predispose to the development of insulin resistance, hypertension and inflammation. Therefore, adipokines are the subject of ongoing clinical trials. The family of adipokines is increasing by the newly discovered peptides. This paper presents the current state of knowledge about retinol binding protein 4 (RBP-4), fasting-induced adipose factor/angiopoietin-like protein 4 (FIAF/ANGPTL4), fibroblast growth factor-21 (FGF21), dipeptidyl peptidase-4 (DPP-4), irisin and their potential role in the pathogenesis of metabolic disorders associated with obesity. The knowledge of the role of newly discovered adipokines may help in the treatment of metabolic syndrome.
-
5.
[Adipocytokines and assay method in metabolic syndrome].
Abe, A
Rinsho byori. The Japanese journal of clinical pathology. 2010;(8):823-9
Abstract
Adipocytokines, such as adiponectin, TNF-alpha, and leptin, are cytokines secreted by visceral adipocytes, and they are associated with metabolic syndrome. Adiponectin is one of the adipocytokines, and is a protein comprised of 244 amino acids. It is known as ACRP30, GBP28, and AdipoQ. Adiponectin is secreted by adipocytes, has three different isoforms, including trimers (low-molecular weight: LMW), hexamers (middle-molecular-weight: MMW), and higher-order oligomeric (high-molecular-weight: HMW) structures, and affects the biological activity. Adiponectin is a clinically relevant parameter measured routinely in subjects at risk of type 2 diabetes and metabolic syndrome. We investigated the adiponectin levels using a number of ELISA assay kits.
-
6.
Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome.
Maury, E, Brichard, SM
Molecular and cellular endocrinology. 2010;(1):1-16
Abstract
Obesity plays a causative role in the pathogenesis of the metabolic syndrome. Adipokines may link obesity to its co-morbidities. Most adipokines with pro-inflammatory properties are overproduced with increasing adiposity, while some adipokines with anti-inflammatory or insulin-sensitizing properties, like adiponectin are decreased. This dysregulation of adipokine production may promote obesity-linked metabolic disorders and cardiovascular disease. Besides considering adipokines, this review will also highlight the cellular key players and molecular mechanisms involved in adipose inflammation. Targeting the changes in the cellular composition of adipose tissue, the underlying molecular mechanisms, and the altered production of adipokines may have therapeutic potential in the management of the metabolic syndrome.
-
7.
[Adipokines and lipids].
Sumarac-Dumanović, M, Jeremić, D
Medicinski pregled. 2009;:47-53
Abstract
Insulin resistance, hyperleptinaemia and low plasma levels of adiponectin are also widely related to features of the MS. The functional capacity of the adipose tissue varies among subjects explaining the incomplete overlapping among the metabolic syndrome and obesity. Far turnover is determined by a complex equilibrium in which insulin is a main factor but not the only one. Chronically inadequate energy balance may be a key factor, stressing the system. In this situation, an adipose tissue functional failure occurs resulting in changes in systemic energy delivery, impaired glucose consumption and activation of self-regulatory mechanisms that extend their influence to the whole body homeostasis system. Lipid metabolism alterations in liver and peripheral tissues are addressed, with particular reference to adipose and muscle tissues, and the mechanisms by which some adipokines, namely leptin and adiponectin, mediate the regulation of fatty acid oxidation in those tissues. The activation of the AMPK (AMP-dependent kinase) pathway, together with a subsequent increase in the fatty acid oxidation, appear to constitute the main mechanism of action of these hormones in the regulation of lipid metabolism. A decreased activation of AMPK appears to have a role in the development of features of the MS. In addition, the alteration of AMPK signalling in the hypothalamus, which may function as a sensor of nutrient availability, integrating multiple nutritional and hormonal signals, may have a key role in the appearance of the MS.
-
8.
Role of adipocytokines in obesity-associated insulin resistance.
Zou, C, Shao, J
The Journal of nutritional biochemistry. 2008;(5):277-86
Abstract
The rapid increase of obese population in the United States has made obesity into epidemic proportion. Obesity is a strong risk factor for metabolic syndrome, type 2 diabetes mellitus, cardiovascular diseases, cancer and other diseases. Compelling evidence has demonstrated that increased adipose tissue mass is not only the consequence of obesity, but also plays a central role in the development of obesity-associated diseases. Recent studies have profoundly changed the concept of adipose tissue from being an energy depot to an active endocrine organ. The development of obesity alters adipocyte-derived hormones or cytokines expression, which provide a link between obesity and impaired insulin sensitivity and metabolic defects in other tissues. This review summarizes the current knowledge on how major adipose-derived hormones or adipocytokines influence insulin sensitivity.
-
9.
Adipokines as emerging mediators of immune response and inflammation.
Lago, F, Dieguez, C, Gómez-Reino, J, Gualillo, O
Nature clinical practice. Rheumatology. 2007;(12):716-24
Abstract
The scientific interest in the biology of white adipose tissue (WAT) has increased since the discovery of leptin in 1994. The description of the product of the gene obese (ob) demonstrated the role of adipose tissue in the physiopathology of obesity-related diseases, and helped to increase the identification of numerous other adipokines, many of a pro-inflammatory nature. It has become increasingly evident that WAT-derived adipokines can be considered as a hub between obesity-related exogenous factors, such as nutrition and lifestyle, and the molecular events that lead to metabolic syndrome, inflammatory and/or autoimmune conditions, and rheumatic diseases. In this Review, we will discuss the progress in adipokine research, focusing particular attention to the roles of leptin, adiponectin, resistin, visfatin, and other recently identified adipokines in inflammatory, autoimmune and rheumatic diseases.